MedTrace Logo

Platelet-lymphocyte and Neutrophil-lymphocyte Ratio in Patients Undergoing Cancer Surgery

NCT04630483 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-05-04

No results posted yet for this study

Summary

Cancer is a major cause of morbidity and mortality worldwide. Despite the use of surgery in an attempt to cure the majority of solid tumors, metastasis from residual cancer cells still remains a major cause of morbidity and mortality. General anesthesia and surgical stress during surgery suppress the immune response by directly affecting the immune system or by activating the hypothalamic-pituitaryadrenal axis and the sympathetic nervous system. The aim of our prospective observational study was to assess the value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio regarding outcome underwent cancer surgery. Primary aim is to assess the preoperative and postoperative values of inhalational anesthesia vs total intravenous anesthesia.

Conditions

  • Cancer
  • Urologic Neoplasms
  • Gynecologic Cancer

Interventions

OTHER

INHA

NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values

OTHER

TIVA

NLR and PLR ratio will be assessed at postoperative 6th and 24th hours compared to preoperative values

Sponsors & Collaborators

  • Medipol University

    lead OTHER

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-23
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630483 on ClinicalTrials.gov